{"disease":{"id":"heterozygous-familial-hypercholesterolemia-hefh","name":"heterozygous familial hypercholesterolemia hefh"},"drugs":{"marketed":[{"drug_id":"caduet","indication_name":"Heterozygous Familial Hypercholesterolemia (HeFH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caduet","generic_name":"Amlodipine Besylate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channel","drug_class":"Dihydropyridine calcium channel blocker","quality_score":76,"revenue":null,"mechanism":"Calcium channel antagonist inhibiting transmembrane calcium influx into vascular and cardiac muscle."},{"drug_id":"lerodalcibep","indication_name":"heterozygous familial hypercholesterolemia (HeFH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lerochol","generic_name":"LERODALCIBEP","company_name":"Lib Therapeutics, Inc.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":45,"revenue":null,"mechanism":"Lerodalcibep works by modulating a specific biological pathway to lower cholesterol levels."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07427472","title":"\"Detection and Follow-up of Coronary Lesions in HeFH (DESTINY-FH Study)\"","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT07058077","title":"A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":153,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT07465263","title":"A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":135,"lead_sponsor_name":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","has_results":false},{"nct_id":"NCT07470723","title":"The ORIGIN-FH Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"University of Wisconsin, Madison","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}